Xconomy: deals News, Articles and Opinions

“deals” Archives

Entry	Author	Date	Location
Backed by $50M, Verseau Launches to Reprogram Immune Cells Against Cancer	Frank Vinluan	10/21/19	Boston
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More	Frank Vinluan	10/18/19	National
Healx Bags $56M to Advance Affordable, AI-Based Orphan Drugs	Mike Ward	10/17/19	National
Alexion to Buy Achillion in $930M Marriage of Rare Disease Drug Firms	Frank Vinluan	10/16/19	Boston
Cyteir Adds $40M for Clinical Test of “Synthetically Lethal” Cancer Drug	Frank Vinluan	10/15/19	Boston
Vir Bio’s IPO Brings In $143M for Tests of Hepatitis B Drug and More	Frank Vinluan	10/11/19	San Francisco
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma	Frank Vinluan	10/10/19	Boston
Five Years After Y Combinator First Admits Biotechs, They’re Dug In	Bernadette Tansey	10/09/19	San Francisco
Akcea, Fresh Off C-Suite Shakeup, Dishes Heart Drug to Pfizer for $250M	Ben Fidler	10/07/19	Boston
Three Biotechs Raise $320M in IPOs, Two Others Pass on Wall Street	Frank Vinluan	10/03/19	National
Icosavax Lands $51M to Bring Vaccine for Respiratory Virus to Clinic	Frank Vinluan	10/03/19	Seattle
Nuance Spinout Cerence Vies With Tech Giants in Voice-AI for Auto	Bernadette Tansey	10/02/19	San Francisco
Viscient Bio Proposes Organovo Merger to Tackle NASH and Go Beyond	Frank Vinluan	10/02/19	San Diego
Meissa Scores $30M to Test Vaccine for Dangerous Respiratory Virus	Bernadette Tansey	09/26/19	San Francisco
Report: IPO Activity Picking Back Up Following Quiet, Volatile Q3	Sarah de Crescenzo	09/25/19	San Diego
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further	Ben Fidler	09/23/19	Boston
Boston Tech Watch: DataRobot, IBM-MIT, Firefly, Aliro, Embr & More	Brian Dowling	09/20/19	Boston
High-Flying Ginkgo Nets Another $290M to Program Cells Like Computers	Frank Vinluan	09/19/19	Boston
WI Watchlist: MSI Data, Cellular Dynamics, WARF, Redox, & More	Jeff Buchanan	09/18/19	Wisconsin
HMS’s $36M Deal to Buy VitreosHealth Combines Complementary Firms	Jeff Buchanan	09/17/19	Texas
Lundbeck Paying Nearly $2B for Alder to Follow Migraine Rivals to Market	Mike Ward	09/16/19	National
Why Menlo Ventures Backed Construction Tech Firm Fieldwire	Bernadette Tansey	09/16/19	San Francisco
SpringWorks and Satsuma Boost This Week’s Biotech IPO Haul to $595M	Frank Vinluan	09/12/19	San Francisco
Shopify Buys 6 River Systems for $450M to Boost Fulfillment Centers	Brian Dowling	09/10/19	Boston
Challenging CRISPR, Trucode Raises $34M for New Gene-Editing System	Frank Vinluan	09/10/19	San Francisco
Home Buying Tech Startup Savvy Lane Lands $2M for West Coast Growth	Jeff Buchanan	09/06/19	Seattle
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds	Frank Vinluan	09/06/19	Boston
Boston Tech Watch: MIT Epstein, Notarize Cash, New Carbonite Execs	Brian Dowling	09/06/19	Boston
WI Watchlist: Epic, Frontdesk, Shine, StartingBlock Madison & More	Jeff Bauter Engel	09/06/19	Wisconsin
Novartis & IFM Team Up Again, With Buyout Option for Autoimmune R&D	Frank Vinluan	09/05/19	Boston
Page 1 of 292	next page »

Underwriters and Partners

Xpertise: Watch + Learn

Sponsored · Whitepaper
Protecting Valuable Life Science Assets & Equipment: Monitoring Solutions
Remain compliant and ensure optimal productivity
XiltriX

Xconomy Insight · Special Report
How to Jump 5 Unforeseen Hurdles to Biotech Success – Startup Sourcebook
Insights, wisdom, and inspiration on what it takes

Xconomy Insight · Webinar
The New Era of Emerging Therapies Webinar Series
Potential cures and treatments for diseases are on the horizon for a growing number of patients, thanks to recent breakthroughs in CRISPR gene-editing technologies and in cell and gene therapy.